Personalis (NASDAQ:PSNL) CMO Richard Chen Sells 3,998 Shares

Personalis, Inc. (NASDAQ:PSNL) CMO Richard Chen sold 3,998 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the transaction, the chief marketing officer directly owned 169,882 shares in the company, valued at approximately $2,755,486.04. The trade was a 2.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Trading Up 0.7%

Personalis stock opened at $16.36 on Wednesday. The company has a 50-day moving average price of $15.09 and a 200 day moving average price of $10.94. Personalis, Inc. has a 12-month low of $4.95 and a 12-month high of $18.89. The stock has a market cap of $1.71 billion, a P/E ratio of -15.01 and a beta of 2.31.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. As a group, analysts forecast that Personalis, Inc. will post -1.07 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on PSNL. Zacks Research upgraded Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a report on Monday, July 20th. Morgan Stanley upped their target price on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.54.

Institutional Investors Weigh In On Personalis

Institutional investors and hedge funds have recently modified their holdings of the company. Merck & Co. Inc. acquired a new position in Personalis in the 2nd quarter valued at about $188,202,236. BlackRock Inc. acquired a new stake in shares of Personalis during the second quarter worth about $94,905,000. Bank of America Corp DE purchased a new position in shares of Personalis in the second quarter valued at approximately $24,395,000. AIGH Capital Management LLC purchased a new position in shares of Personalis in the second quarter valued at approximately $22,981,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Personalis by 8.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.